Jiangzhong Pharmaceutical Co Ltd (600750) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangzhong Pharmaceutical Co Ltd (600750) has a cash flow conversion efficiency ratio of -0.001x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-2.91 Million ≈ $-425.37K USD) by net assets (CN¥4.70 Billion ≈ $688.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Jiangzhong Pharmaceutical Co Ltd (600750) total market value for the company's overall valuation and market capitalisation.
Jiangzhong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Jiangzhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jiangzhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangzhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Jiangzhong Pharmaceutical Co Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cosmax Inc
KO:192820
|
0.115x |
|
AvidXchange Holdings Inc
NASDAQ:AVDX
|
0.034x |
|
Suzhou Crystal Clear Chemical Co Ltd
SHE:300655
|
0.062x |
|
Easyhome New Retail Group Co Ltd
SHE:000785
|
0.039x |
|
Tera Yatirim Menkul Degerler A.S.
IS:TERA
|
-0.394x |
|
BHP Group Limited
LSE:BHP
|
0.205x |
|
Via Transportation, Inc.
NASDAQ:VIA
|
-0.017x |
|
Extreme Networks Inc
NASDAQ:EXTR
|
0.523x |
Annual Cash Flow Conversion Efficiency for Jiangzhong Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Jiangzhong Pharmaceutical Co Ltd from 1998 to 2025. View 600750 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.70 Billion ≈ $688.21 Million |
CN¥970.87 Million ≈ $142.07 Million |
0.206x | +17.40% |
| 2024-12-31 | CN¥4.47 Billion ≈ $654.34 Million |
CN¥786.25 Million ≈ $115.05 Million |
0.176x | -21.44% |
| 2023-12-31 | CN¥4.63 Billion ≈ $677.30 Million |
CN¥1.04 Billion ≈ $151.58 Million |
0.224x | -1.26% |
| 2022-12-31 | CN¥4.51 Billion ≈ $659.65 Million |
CN¥1.02 Billion ≈ $149.51 Million |
0.227x | +13.26% |
| 2021-12-31 | CN¥4.58 Billion ≈ $670.56 Million |
CN¥917.04 Million ≈ $134.19 Million |
0.200x | +13.06% |
| 2020-12-31 | CN¥4.25 Billion ≈ $622.10 Million |
CN¥752.50 Million ≈ $110.11 Million |
0.177x | +8.34% |
| 2019-12-31 | CN¥3.92 Billion ≈ $574.26 Million |
CN¥641.18 Million ≈ $93.82 Million |
0.163x | +9.32% |
| 2018-12-31 | CN¥3.25 Billion ≈ $476.08 Million |
CN¥486.25 Million ≈ $71.15 Million |
0.149x | +248.77% |
| 2017-12-31 | CN¥2.92 Billion ≈ $426.61 Million |
CN¥124.93 Million ≈ $18.28 Million |
0.043x | -83.94% |
| 2016-12-31 | CN¥2.62 Billion ≈ $382.77 Million |
CN¥698.05 Million ≈ $102.15 Million |
0.267x | +23.02% |
| 2015-12-31 | CN¥2.35 Billion ≈ $344.55 Million |
CN¥510.78 Million ≈ $74.74 Million |
0.217x | +29.69% |
| 2014-12-31 | CN¥2.13 Billion ≈ $312.15 Million |
CN¥356.80 Million ≈ $52.21 Million |
0.167x | +218.82% |
| 2013-12-31 | CN¥2.13 Billion ≈ $312.16 Million |
CN¥111.92 Million ≈ $16.38 Million |
0.052x | -52.42% |
| 2012-12-31 | CN¥2.05 Billion ≈ $300.43 Million |
CN¥226.38 Million ≈ $33.13 Million |
0.110x | +25.64% |
| 2011-12-31 | CN¥1.92 Billion ≈ $280.62 Million |
CN¥168.30 Million ≈ $24.63 Million |
0.088x | -29.76% |
| 2010-12-31 | CN¥1.78 Billion ≈ $260.34 Million |
CN¥222.29 Million ≈ $32.53 Million |
0.125x | -64.56% |
| 2009-12-31 | CN¥1.07 Billion ≈ $157.00 Million |
CN¥378.32 Million ≈ $55.36 Million |
0.353x | +27.13% |
| 2008-12-31 | CN¥969.41 Million ≈ $141.86 Million |
CN¥268.87 Million ≈ $39.34 Million |
0.277x | +51.28% |
| 2007-12-31 | CN¥837.97 Million ≈ $122.62 Million |
CN¥153.63 Million ≈ $22.48 Million |
0.183x | +148.45% |
| 2006-12-31 | CN¥748.62 Million ≈ $109.55 Million |
CN¥55.24 Million ≈ $8.08 Million |
0.074x | -73.89% |
| 2005-12-31 | CN¥702.13 Million ≈ $102.74 Million |
CN¥198.45 Million ≈ $29.04 Million |
0.283x | +612.79% |
| 2004-12-31 | CN¥662.81 Million ≈ $96.99 Million |
CN¥26.28 Million ≈ $3.85 Million |
0.040x | -67.88% |
| 2003-12-31 | CN¥639.80 Million ≈ $93.62 Million |
CN¥78.98 Million ≈ $11.56 Million |
0.123x | -25.18% |
| 2002-12-31 | CN¥575.21 Million ≈ $84.17 Million |
CN¥94.90 Million ≈ $13.89 Million |
0.165x | +120.25% |
| 2001-12-31 | CN¥551.04 Million ≈ $80.63 Million |
CN¥41.28 Million ≈ $6.04 Million |
0.075x | -66.43% |
| 2000-12-31 | CN¥545.76 Million ≈ $79.86 Million |
CN¥121.77 Million ≈ $17.82 Million |
0.223x | +625.92% |
| 1999-12-31 | CN¥516.08 Million ≈ $75.52 Million |
CN¥-21.89 Million ≈ $-3.20 Million |
-0.042x | -3.26% |
| 1998-12-31 | CN¥277.86 Million ≈ $40.66 Million |
CN¥-11.42 Million ≈ $-1.67 Million |
-0.041x | -- |
About Jiangzhong Pharmaceutical Co Ltd
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsu… Read more